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Infusions and decoctions of Cymbopogon ambiguus have been used traditionally in Australia for the treatment of headache, chest
infections and muscle cramps. The aim of the present study was to screen and identify bioactive compounds from C. ambiguus
that could explain this plant’s anti-headache activity. A dichloromethane extract of C. ambiguus was identiﬁed as having activity in
adenosine-diphosphate-induced human platelet aggregation and serotonin-release inhibition bioassays. Subsequent fractionation
of this extract led to the isolation of four phenylpropenoids, eugenol, elemicin, eugenol methylether and trans-isoelemicin. While
both eugenol and elemicin exhibited dose-dependent inhibition of ADP-induced human platelet serotonin release, only eugenol
displayed potent inhibitory activity with an IC50 value of 46.6μM, in comparison to aspirin, with an IC50 value of 46.1μM. These
ﬁndings provide evidence to support the therapeutic eﬃcacy of C. ambiguus in the non-conventional treatment of headache and
inﬂammatory conditions.
1.Introduction
The native Australian lemongrass species, Cymbopogon
ambiguus A. Camus. (Poaceae) is a strongly aromatic peren-
nial grass found on rocky hillsides throughout the Northern
Territory of Australia [1] .T h el e a v e sh a v eb e e nu s e d
traditionally to treat chest infections, sores, muscle cramps
as well as headache and associated complaints (infusions
and decoctions) [1–3]. Interestingly, a study on Australian
medicinal plants identiﬁed very weak anti-viral (Ross River
Virus) activity in a leaf extract of C. ambiguus [4], while
another study found no anti-bacterial activity in extracts
of Australian C. ambiguus against four Gram-positive and
four Gram-negative bacterial species [5]. Little is known
about the chemical constituents present in C. ambiguus apart
from a GC-MS study by Barr et al. [3], which identiﬁed
camphene, borneol, limonene, α-pinene, α-terpineol, cam-
phor, isoborneol, 4-terpineol, myrcene, β-ocimene as being
presentintheessentialoil.Nothinghasbeenreportedtodate
in relation to substantiating its use as a non-conventional
traditional remedy for headache, apart from our original
report showing that dichloromethane (DCM) (more potent
extract) and methanolic (MeOH) extracts displayed potent
inhibition of human platelet aggregation and serotonin (5-
HT, 5-hydroxytryptamine) release [6]. To further investigate
the basis for use of C. ambiguus as a remedy for headache,
we report here the isolation and identiﬁcation of principal
bioactive constituents causing inhibition of human platelet
aggregation and serotonin (5-HT) release.
Cymbopogon ambiguus is a headache remedy used in
Australiantraditionalmedicineforgeneralizedheadachedis-
orders. Headaches associated with nausea, such as migraine
are complex disorders, with abnormalities in platelet func-
tion reported. Altered 5-HT transport, decreased platelet
5-HT content, altered platelet cytosolic free-calcium con-
centrations and varying sensitivity to platelet agonists such
as adenosine diphosphate (ADP) and collagen have been
reported in association with headache/migraine episodes [7–
14]. The serotonergic system is thus thought to play an
important role in the pathophysiology of these disorders
[15–20]. We and others have previously reported on the use
of platelets as a model to assess the therapeutic seroton-
ergic potential of tested chemicals in relation to potential
headache/migraine treatment [6, 21, 22].2 Evidence-Based Complementary and Alternative Medicine
Cymbopogon ambiguus has been used as a traditional
Australian aboriginal headache treatment and our studies
have shown that it displays potent anti-platelet activity.
To identify the bioactive constituent(s) responsible for this
activity, lemongrass leaves were sequentially extracted with
DCM then MeOH. Fractionation of the DCM extract led to
the identiﬁcation of four phenylpropenoids as the principal
constituents. We describe herein the isolation and puriﬁca-
tion of these four phenylpropenoids from C. ambiguus along
withpharmacologicalevaluationoftwoofthesecompounds.
This is the ﬁrst report identifying speciﬁc constituents that
underpin the use of C. ambiguus as a non-conventional
traditional Australian anti-headache medicine.
2. Methods
2.1. Plant Collection. Cymbopogon ambiguus (whole plant)
was collected in 1998 in the vicinity of Alice Springs,
Northern Territory, Australia. Identity of the material was
conﬁrmed by the Alice Springs Herbarium, with voucher
specimens deposited at the Herbarium and also in the
Genomics Research Centre, Gold Coast campus, Griﬃth
University (sample ID: DN3081).
2.2. Extraction and Isolation. Dried whole plants (283g)
of C. ambiguus were powdered and exhaustively extracted
(vigorous stirring in 2.5l of solvent for 3h at 22◦C, then
procedure repeated) with DCM followed by MeOH at room
temperature The DCM extract was then concentrated and
dried under reduced pressure (∼50mmHg, 30◦C) to give a
dark green aromatic solid residue (7.53g) and the residue
loaded onto a normal phase chromatography column (silica
gel, 150g, Merck, 60μM, 4.3×11.7cm). The column was
then eluted by passing 600ml volume through the column
from 10% hexane in chloroform, to 100% hexane in 10%
increments. Fractions eluted with 50% and 60% hexane
were both found to exhibit signiﬁcant inhibition of ADP-
induced platelet [14C]5-HT release. Analytical HPLC [Luna
C18,5μM analytical, 4.6mm×250mm, photo-diode-array
(PDA) detection at 270nm, 1.0mlmin−1, method: 25%–
35% acetonitrile/H2O gradient over 10min, followed by
an increase to 45% acetonitrile over a further 50min]
of these fractions indicated ﬁve common constituents,
which were separated by semi-preparative HPLC [Luna C18,
5μM, 10mm×250mm, PDA, 4.5ml min−1, method as
above] to give the known compounds: eugenol (4-allyl-2-
methoxyphenol) (1) (75.4mg, 0.02% w/w); elemicin (5-
allyl-1,2,3-trimethoxybenzene) (2) (520mg, 0.18% w/w);
eugenol methylether (4-allyl-1,2-dimethoxybenzene) (3)
(322mg, 0.11% w/w); and trans iso-elemicin (4) (1,2,3-
trimethoxy-5-(1-propenyl) benzene) (162mg, 0.06% w/w)
(Figure 3).
2.3. Chemicals and Solvents. ADP, acetyl salicylic acid (ASA
or aspirin), dimethyl sulfoxide (DMSO) and deuterated
chloroform (CDCl3) were all obtained from Sigma chem-
ical company (St Louis, USA). 14C-5-hydroxytryptamine
(14C-5-HT) (Amersham, speciﬁc activity 57mCimmol−1,
50μCiml−1). All solvents used were of HPLC grade, includ-
ing acetonitrile (CH3CN) (omnisolv. EM Science, Merck),
chloroform (CHCl3) (chromasolv. Riedel-de Haen), DCM
(chromosolv. Riedel-de Haen), ethyl acetate (Banksia Scien-
tiﬁc Co. Pty. Ltd.), hexane (Mallinckrodt chromAR HPLC)
and methanol (Omnisolv, EM Science, Merck).
2.4.CharacterizationofIsolatedCompounds. Structuralchar-
acterization of the four phenylpropenoids was achieved by
mass spectrometry (MS) (Bruker Daltonics BioAPEX 47e),
extensive NMR experiments (Bruker AC-300, Karlsruhe,
Germany) (1H, 1H-1HC O S Y ,1H-13C HMBC, JMOD) and
comparison of 1H NMR (300 MHz, CDCl3) data (see below)
with previously reported assignments. Eugenol (1)[ 23]: 1H
NMR δ 3.33 (d, 2H, 3J = 6.7Hz, CH2); 3.88 (s, 3H, OCH3);
5.06 (dd, 1H, 2J = 2Hz, 3Jcis = 10Hz, HCHCHCH2); 5.07
(dd, 1H, 2J = 2Hz, 3Jtrans = 17Hz, HCHCHCH2); 5.50
(OH); 5.93 (ddd, 1H, 3Jcis = 10Hz, 3Jtrans = 17Hz, 3J =
6.7Hz, HCHCHCH2); 6.67–6.72 (m, 2H, CCHCHC(OH),
CCHC(OCH3));6.86(dd,1H,Jortho = 8.5Hz,Jmeta = 4.2Hz,
CCHCHC(OH). MS calculated for C10H13O2 [M +H ] +:
165.08. Found: 165.08. Elemicin (2), [24]: 1HN M Rδ 3.33
(d, 2H, 3J = 6.6Hz, CH2); 3.82 (s, 3H, OCH3); 3.84 (s, 6H,
(H3CO)CC(OCH3)C(OCH3); 5.08 (dd, 1H, 2J = 1.8Hz,
3Jcis = 10Hz, HCHCHCH2); 5.11 (dd, 1H, 2J = 1.8Hz,
3Jtrans = 17Hz, HCHCHCH2); 5.95 (ddd, 1H, 3Jcis = 10Hz,
3Jtrans = 17Hz, 3J = 6.6Hz, HCHCHCH2); 6.40 (s, 2H,
2×aromatic H). MS calculated for C12H16O3Na [M +N a ] +:
231.11. Found: 231.11. Eugenol methylether (3)[ 23]; 1H
NMR δ 3.31 (d, 2H, 3J = 6.6Hz, HC=CH2); 3.84 (s, 3H,
OCH3); 3.85 (s, 3H, OCH3); 5.04 (dd, 1H, 2J = 1.5Hz,
3Jcis = 10.1Hz, HCHCHCH2); 5.05 (dd, 1H, 2J = 1.5Hz,
3Jtrans = 16.8Hz, HCHCHCH2); 5.95 (ddd, 1H, 3Jcis =
10.1Hz, 3Jtrans = 16.8Hz, 3J = 6.6Hz, HCHCHCH2); 6.75
(m, 3H, 3Jortho = 8.4Hz, 4Jmeta = 1.4Hz, 3×aromatic
H). MS calculated for C11H15O2[M +H ] +: 179.09. Found:
179.09. trans-Isoelemicin (4)[ 25]; 1HN M Rδ 1.86 (dd, 3H,
3J = 6.4Hz, 4J = 1.5H C C H3); 3.81 (s, 3H, OCH3); 3.83 (s,
6H, 2 × OCH3); 6.13 (dq, 1H, 3Jtrans = 15.6Hz, 3J = 6.4Hz,
HCHCHCH2); 6.31 (dd, 1H, 4J = 1.5Hz, 3Jtrans = 15.6Hz,
HCCHCH3); 6.54 (s, 2H, 2×aromatic H). MS calculated for
C12H17O3[M +H ] +: 209.11. Found: 209.11.
2.5. Platelet Aggregation and [14C]-5HT Release Bioassays.
The bioassays utilised are based on a modiﬁed published
method, described previously by our group [26]a n db y
Groenewegen and Heptinstall [27]. Fresh blood (45ml) was
collected from healthy human volunteers (20- to 35-year
old, not taking aspirin or other drugs likely to interfere
with platelet function for at least 2 weeks prior to blood
sampling). Platelet aggregation and 5-HT release were
measured simultaneously. [14C]5-HT (6 μl) (speciﬁc activity
50μCiml−1) was added to 9ml of citrated blood to label
intracellular storage granules. Platelet-poor plasma (PPP)
and platelet-rich plasma (PRP) fractions were prepared, with
the PRP being adjusted to 300×109 platelets/l by dilution
with PPP. A sample consisting of 450μL of PPP and 100μL
of either, PBS with 1% ethanol or DMSO (control), orEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Bioassay-guided fractionation of C. ambiguus (whole plant) to isolate compounds (1–4).
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Figure 2: HPLC chromatogram of the combined 50:50 and 60:40
hexane/CHCl3 fractions: eugenol (33.8min); elemicin (49.1min);
eugenol methylether (50.7min); trans-iso-elemicin (53.3min).
the test sample, was initially measured in order to set 100%
aggregation (a decrease in optical density reﬂects an increase
inplateletaggregation).Theﬁnalconcentrationofethanolor
DMSO did not exceed 0.2% (v/v). Labeled PRP (450 μl) was
thenstirred(1000r.p.m.at37◦C)for3mininthepresenceof
100μl of the C. ambiguus extract (or isolated compound) or
PBS containing either 1% ethanol or DMSO (control). ADP
(50μl) was then added to samples, and platelet aggregation
was monitored for 6 minutes. Platelet aggregation was
measured in a four-channel platelet aggregometer (Monitor
IV plus, Helena Laboratories, Beaumont, USA). Samples of
PRP were incubated without the addition of ADP to measure
the amount of [14C] 5-HT that was not taken up by platelets,
and which may have been spontaneously released during the
procedure (blank). ASA (50 μl, 14mm) was then added to
irreversibly inhibit further 5-HT release, and samples were
placed on ice for ∼5min. Samples were then centrifuged
(6000r.p.m.) for 8min, and duplicate 50μla l i q u o t sw e r e
taken from the supernatant and counted (Wallac 1450,
MicroBeta counter) for determination of % [14C] 5-HT
release. Percentage 5-HT release was calculated as follows:
Amount of

14C

5 −HT −blank
Total counts −blank
×100%. (1)
IC50 values were generated using the software of Graph-
pad prism (3.0).
2.6. Bioethics Clearance. Blood samples for the platelet
studies were collected by a qualiﬁed phlebotomist and the
study had full ethical clearance from the Griﬃth University
Ethics Committee for experimentation on human subjects.
Informedwrittenconsentwasobtainedfromallparticipants.
2.7. Statistical Analysis. Platelet aggregation and 5-HT
release response, was expressed as a percentage of the control
value. IC50 values (concentration producing 50% inhibition
of the maximum response) were calculated by non-linear
regression analysis of the dose-response curves using the
software of Graphpad Prism (3.0). Results are presented as
the means±SEM of n experiments.4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Structure of the four phenylpropenoides [eugenol (4-allyl-2-methoxyphenol) (1); elemicin (5-allyl-1,2,3-trimethoxybenzene) (2);
eugenol methylether (4-allyl-1,2-dimethoxybenzene) (3)a n dtrans iso-elemicin (1,2,3-trimethoxy-5-(1-propenyl) benzene) (4)] isolated
from the Australian native lemongrass species C. ambiguus.
3. Results
3.1. Extraction. Both DCM and MeOH extracts of C.
ambiguus produced a dark green residue that was strongly
aromatic (lemon scented). The total weight of the DCM
extract after drying was 7.53g, and for the MeOH extract,
16.84g.
3.2. Isolation and Structural Characterization. Silica column
chromatography (10% gradient increments from 10:90
hexane:CHCl3 through to 100:0 hexane:CHCl3 elution) of
theDCMfractionelutedanactive50:50–60:40hexanefrac-
tion. The dried residue (weighing∼1.16g) was resuspended
in CH3CN and fractionation of the soluble components
utilising HPLC, aﬀorded ﬁve compounds (Figures 1 and 2).
Four of these compounds were puriﬁed further (purity was
ascertained by HPLC analysis) and then subjected to MS and
NMR analysis. The ﬁfth compound (eluting at 54.11min)
(Figure2)wasnotsuccessfullypuriﬁedandwasthereforenot
structurally characterised in these studies.
The assignment of the structures for eugenol, elemicin,
eugenol methylether and trans-iso-elemicin (Figure 3),
which are known compounds, was established on the basis
of the 1H NMR and MS data. Chemical shifts were iden-
tical to those previously reported (see Methods section—
Characterization of Isolated Compounds). The chemical
structure and identity of each compound is shown in
Figure3.Theisolationofthesecompoundswasguidedbythe
activity of the active hexane fraction (50% and 60%) in the
ADP-induced platelet 5-HT release bioassay. Both eugenol
and elemicin were investigated pharmacologically in further
studies.
3.3. Platelet Aggregation and [14C]-5HT Release Bioassay.
For the platelet aggregation and 5-HT release studies, a
submaximal concentration of ADP was used to stimulate
the platelet response. Elemicin’s aﬀect on inhibiting ADP-
induced platelet aggregation was less potent than eugenol
in our results and therefore we focussed our interests on
eugenol. Eﬀects of increasing eugenol concentrations (0, 46,
61 and 152μM) on the ADP-induced platelet aggregation
clearly showed that concentrations above 61μM did not
inhibit platelet aggregation further. Interestingly, eugenol
and elemicin exhibited dose-dependent inhibition of ADP
(2μM)-induced platelet 5-HT release, although eugenol at
a much lower concentration than elemicin (see Table 1
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Figure 4: Dose-dependent inhibition of ADP (2μM)-induced
human platelet [14C]5-HT release. Results represent the mean of
duplicate analyses performed on PRP obtained from four diﬀerent
individuals.
and Figure 4 (eugenol data only)). Concentration ranges
of eugenol, elemicin and aspirin chosen to examine their
inhibitory activity on human platelet 5-HT release were
2.8×10−6 to 2.8×10−4 M, 1.7×10−4 to 3.5×10−3 and
2.5×10−6 to 2.5×10−4 M, respectively. Despite structural
similarities, there were remarkable diﬀerences in the level
of activity between eugenol and elemicin [1]. Eugenol was
up to 50 times more potent than elemicin, with IC50 values
calculated to be 46.6μM and 1729.8μM, respectively. ASA
is an irreversible inhibitor of platelet cyclooxygenase (COX)
activity, and still remains the standard to which other anti-
platelet drugs are often compared [28]. The dose-dependent
eﬀect of eugenol compared favorably to ASA (Figure 4),
which exhibited an IC50 value of 46.1μM in these studies.
4. Discussion
Bioassay-directed fractionation of the DCM extract of C.
ambiguus aﬀorded the isolation and structural character-
ization of four compounds, eugenol, elemicin, eugenol
methylether and trans-iso-elemicin. Like 1,8-cineole (the
major active constituent of Melaleuca, Eucalyptus andEvidence-Based Complementary and Alternative Medicine 5
Table 1: IC50 values for components of C. ambiguus and aspirin
against ADP-induced platelet 5-HT release.
Compound IC50 (μM)
Eugenol 46.6±3.7
Elemicin 1729.8±147.5
Acetylsalicylic acid (ASA, Aspirin) 46.1±3.1
Results represent IC50 ±SEM (n = 4) as determined by the software of
Graphpad prism (3.0).
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Figure 5: Platelet aggregation trace showing an example of the
eﬀect of low to high doses (0, 46, 61 and 152μM) of eugenol on
ADP-inducedplateletaggregation.Thechangeinlighttransmission
is represented as percentage of platelet aggregation using a four-
channel platelet aggregometer. Results are duplicates obtained from
PRP from two diﬀerent individuals.
Prostanthera sp.), eugenol and elemicin are volatile monoter-
penoids (i.e., C10 compounds) with anti-inﬂammatory
aﬀects [29]. Indeed, other similar compounds have pre-
viously been isolated from Cymbopogon sp. including,
limonene and α-terpineol, which are generally common
components of citrus oils [30, 31]. Eugenol and elemicin
have also been isolated from several other plants includ-
ing Myristica fragrans (nutmeg) and Syzygium aromaticum
(clove oil), where they are believed to be some of the major
constituents responsible for the biological activities of these
plants [29, 32, 33]. Elemicin has been identiﬁed previously
in another Australian native, Cymbopogon procerus [3];
however, this is the ﬁrst report of eugenol in the Cymbopogon
sp. and indeed the ﬁrst evidence for the presence of these
compounds in the Australian native lemongrass species, C.
ambiguus.
In these studies, eugenol was found to be up to 50-fold
more active than elemicin at inhibiting 5-HT release from
humanplatelets.Fromdose-dependantresponsesIC50 values
of 46.6μM and 1729.8μM were determined, respectively, in
our 5-HT release inhibition assay (Figure 4 and Table 1]. In
previous studies using rabbit platelets, eugenol was found
to be up to 1000 times more potent than elemicin and was
found to compare favorably with indomethacin [34]. An
additional study found eugenol to be 29 times more potent
than aspirin at inhibiting arachidonic acid-induced human
platelet aggregation [35]. Based on reports in the literature
and the structural characteristics of eugenol methylether and
trans-iso-elemicin, which were also isolated in the active
fraction, these two compounds were not investigated further
in our pharmacological studies [34]. Although, interestingly
it has been demonstrated that eugenol methylether has anti-
nociceptive eﬀects on formalin-induced hyperalgesia [36].
However, our interests and discussion here focus on eugenol
due to its principal activity in our bioassays.
Studieshavedemonstratedthateugenolhasanti-oxidant,
anti-inﬂammatory, anti-platelet (using rabbit platelets),
anti-nociceptive and anti-ulcerogenic eﬀects [37–42]. Fur-
thermore, this drug has also been shown to potentiate
GABAA transmission [43, 44] .E u g e n o li sr e p o r t e dt oc a u s e
inhibitionofthromboxaneA2 andB2 formation,withoutany
inﬂuence on the lipoxygenase pathway and appears to be an
inhibitor of COX activity similarly to aspirin. In addition,
more recent data indicates that this drug inhibits the rise in
intracellular Ca2+ caused by collagen, adrenalin, ADP and
AA [38]. Hence, eugenol appears to have pharmaceutical
features that might be considered ideal characteristics of a
migraine treatment. In support of these earlier studies [29],
our results provide evidence that eugenol does not have
signiﬁcant eﬀects on the primary phase of ADP induced
platelet aggregation. Concentrations of eugenol above 61μM
did not inhibit platelet aggregation further (Figure 5)a n d
this result strongly suggests that eugenol selectively targets
the second phase of platelet aggregation. This second phase
of aggregation involves the “release reaction,” which is
dependent on cytosolic increases in Ca2+ and the activation
of PLC (phospolipase C) and the COX pathway [45], which
mediate platelet dense granule secretion. Therefore, 5-HT
release could be completely inhibited even when aggregation
is not. In line with this, high concentrations of eugenol that
inhibited 5-HT release only inhibited the second phase of
platelet aggregation (Figures 4 and 5]. The modulation of 5-
HT release was the principal pathway we were interested in
investigating.
Aspirin is a potent anti-inﬂammatory analgesic, known
to cause inhibition of the COX pathway, namely the COX-
1 and COX-2 isoforms of this enzyme. In general, aspirin
is used to assist in prevention of heart attacks, strokes,
arthritis, diabetes and migraines and may also slow the
mental decline of old age or provide neuroprotection in
a mouse model of Parkinson’s disease [46, 47]. Previous
studies have also shown that a single concentration of
eugenol,inhibitsbothCOX-1andCOX-2enzymes[48].Our
results show that eugenol exhibits pharmacological eﬀects
thatresemblethoseofaspirinandthisdatasupportsprevious
evidence that eugenol is a COX inhibitor and acts as a
potent anti-platelet drug. Interestingly, eugenol is reported
to exhibit analgesic properties [38] and has also been used
to treat gastrointestinal upsets and chronic diarrhoea and
is approved by the Food and Drug Administration of the
USA. It is noteworthy that other traditional medicines6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Schematic representation of platelet activation and the inhibitory eﬀects of eugenol (from the DCM extract of C. ambiguus)o n
ADP-induced 5-HT release and platelet aggregation.
known to modulate 5-HT activity have also been reported
as treatments for gastrointestinal tract [49] and allergenic
disorders [50]. Eugenol is also likely to have potential in
the treatment of other diseases related to platelet aggrega-
tion, such as, thrombosis, transient ischemia, inﬂammation,
tumor growth and promotion of atherosclerosis [51, 52].
However, there is only limited data relating to its potential
use as an anti-headache/migraine or anti-platelet drug [29].
Few side eﬀects have been reported in relation to the use of
eugenol.Onereportonitsuseasatraditionaldentalmaterial
does however document local irritative and cytotoxic eﬀects
along with hypersensitivity reactions when used in contact
with soft oral tissues [53].
5. Conclusions
In conclusion, four known compounds (eugenol, elemicin,
e u g e n o lm e t h y le t h e ra n dtrans-isoelemicin) were isolated
from the DCM extract of C. ambiguus. Eugenol and elemicin
were identiﬁed as contributing the principal activity of
this extract and demonstrated dose-dependent inhibition of
ADP-induced human platelet [14C]5-HT release, with IC50
values of 46.6μM and 1729.8μM, respectively. Eugenol was
also identiﬁed as having potent aﬀects on the second-phase
of platelet activation. The results of these studies provide evi-
dence identifying speciﬁc constituents (principally eugenol)
that have anti-platelet activity (Figure 6) that establish
the basis of the therapeutic activity and traditional use of
C. ambiguus as a non-conventional remedy for headache
conditions.
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